Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 30Observational 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Magnetic Resonance Spectroscopy 24Surveys and Questionnaires 23Radiotherapy 23Blood Specimen Collection 20Radiosurgery 17Temozolomide 13Magnetic Resonance Imaging 12Surgical Procedures, Operative 10Neuropsychological Tests 10Radiation 8Polymerase Chain Reaction 8Immunohistochemistry 8Gene Expression Profiling 8Amplified Fragment Length Polymorphism Analysis 8Mental Status and Dementia Tests 6Phlebotomy 5Observation 5Flow Cytometry 5Watchful Waiting 4Quality of Life 4Psychiatric Rehabilitation 4Microarray Analysis 4Interviews as Topic 4Drug Therapy 4Biopsy 4vorasidenib 3gadobenic acid 3Transurethral Resection of Bladder 3Radiotherapy, Intensity-Modulated 3Physical Examination 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × dinutuximab × CNS × Clear all
NCT02693171 2019-08-05

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

United Therapeutics

Terminated
13 enrolled 9 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡